
99%+ Purity
COA Included
Sealed Vials
AOD-9604
Precision Fat Loss—No Hormone Trade-Offs
Lipolysis fragment of HGH
Key Benefits
- Selective activation of fat tissue receptors
- May promote breakdown of stored fat
- Supports inhibition of new fat formation
- Preferential effects on adipose tissue
- Minimal impact on muscle tissue
- Sustained activity for 6-8 hours
- Avoids unwanted anabolic effects
Want to purchase this peptide?
About AOD-9604
AOD-9604 represents a breakthrough in targeted fat metabolism research, offering the fat-burning potential of growth hormone in a precisely engineered 16-amino acid fragment. This innovative peptide may support body composition goals by selectively activating beta-3 adrenergic receptors in fat tissue, promoting the breakdown of stored fat while inhibiting new fat formation. Research suggests AOD-9604 works through dual pathways - activating hormone-sensitive lipase to mobilize existing fat stores and stimulating AMPK pathways to enhance fat oxidation. Unlike full-length growth hormone, this selective fragment demonstrates preferential effects on adipose tissue without significantly impacting muscle growth or blood sugar metabolism. Studies indicate peak activity occurs within 2-4 hours of administration, with effects sustained for 6-8 hours. While AOD-9604 remains investigational and requires further clinical validation, early research suggests promising potential for those seeking targeted approaches to body composition management through scientifically-grounded metabolic pathways.
Research Background
AOD-9604 represents a targeted approach to harnessing growth hormone's fat-burning properties while avoiding unwanted side effects. This synthetic peptide works by activating beta-3 adrenergic receptors in fat tissue and stimulating AMPK pathways, which together promote the breakdown of stored fat (lipolysis) while preventing new fat formation (lipogenesis). Unlike full growth hormone, AOD-9604 doesn't significantly increase IGF-1 levels or affect blood sugar, making it a more selective tool for body composition management. Research has focused on three primary areas: 1) Understanding its selective receptor binding that targets fat cells specifically, 2) Optimizing dosing protocols for maximum fat loss with minimal side effects, and 3) Evaluating long-term safety in various populations. While promising preclinical and early human studies suggest potential benefits for fat loss and metabolic health, AOD-9604 remains investigational and requires additional clinical validation before regulatory approval.
Dosing Protocol
| Level | Dose | |
|---|---|---|
Beginner | 0.5 mg | |
Intermediate | 1 mg | |
Advanced | 1.5 mg | |
Maximum | 2 mg |
Select a dosing level and click Calculate to plan your protocol.
Vials Required
17
84.0 mg needed ÷ 5 per vial
Total Investment
$935
$55.00 per vial
Per Dose
0.20 mL
20 units on U-100 syringe
Doses per Vial
5
5 ÷ 1.00 mg/dose
* Calculations based on standard reconstitution protocols. Consult research guidelines for specific applications.
Educational Resources
Download educational materials and research documentation for AOD-9604.
AOD-9604 Cheat Sheet
Dosing protocols, reconstitution & storage guide
Featured in These Stacks
GH Axis Bundel
GH Axis Inventory
The GH Axis Inventory is the primary performance multiplier inside the peptide model. Growth hormone signaling influences body composition, tissue repair, recovery bandwidth, and metabolic responsiveness. Without this axis, fat loss becomes muscle loss, recovery slows, and training output plateaus. This inventory is intentionally layered to provide flexibility across intensity levels: Sermorelin serves as entry-level endogenous stimulation. Tesamorelin (10mg & 20mg) targets visceral fat and provides scalable leverage. Tesamorelin / Ipamorelin blends amplify GH pulses for structured recomposition. Tesamorelin / CJC / Ipamorelin creates triple-pathway synergy. CJC-1295 (DAC & No DAC) allows duration control — pulse vs sustained. Ipamorelin provides clean adjunct stimulation. IGF-1 LR3 delivers downstream growth expression. Fragment 176-191 targets fat mobilization pathways. This layered approach prevents over-reliance on a single compound and allows protocols to adapt to client progression. As volume increases, GH flexibility becomes revenue protection — because it prevents stagnation. Strategically, the GH axis: Enhances recomposition efficiency Preserves lean mass during fat loss Accelerates recovery Supports connective tissue repair Increases training capacity At scale, GH inventory becomes a central profit driver. It supports both base stacks and premium builds. It is not optional — it is structural. This is not a single product category. It is a signaling architecture built to scale results.
Includes
Weight Loss ULTIMATE SHRED
Weight Loss
This is not a “fat burner stack.” It is a layered metabolic architecture designed to systematically control intake, improve nutrient partitioning, increase mitochondrial output, mobilize stored fat, and preserve lean mass — in that order. 1️⃣ Foundation: Insulin & Appetite Control Retatrutide anchors the system. By targeting GLP-1, GIP, and glucagon pathways simultaneously, it reduces appetite, improves glucose handling, and increases energy expenditure. If insulin is unstable, nothing downstream works efficiently. This layer reduces fat-storage signaling and improves nutrient partitioning so calories are directed toward muscle instead of adipose tissue. 2️⃣ Mitochondrial Output Layer The Mito Blend (SS-31, MOTS-c, 5-Amino-1MQ), combined with SLU-PP-332 and BAM15, upgrades cellular energy mechanics. SS-31 improves mitochondrial membrane efficiency. MOTS-c enhances glucose utilization and metabolic flexibility. 5-Amino-1MQ supports NAD+ preservation and metabolic turnover. SLU-PP-332 activates PGC-1α to mimic endurance training at the cellular level. BAM15 increases calorie burn through controlled mitochondrial uncoupling. This layer ensures liberated fat is oxidized instead of recycled. It increases baseline metabolic throughput without relying on stimulants. 3️⃣ Growth Hormone Axis Optimization Tesamorelin or CJC-1295/Ipamorelin restores physiologic GH pulsatility. Proper GH signaling preferentially targets visceral fat while supporting sleep quality, connective tissue repair, and lean mass preservation. This is not replacement therapy — it is rhythm restoration. The GH layer enhances lipolysis and improves recovery so training output can increase without overtraining. 4️⃣ Direct Lipolytic Signaling HGH Frag 176-191 and AOD-9604 act downstream of GH, signaling adipose tissue to release stored fat. These compounds do not meaningfully elevate systemic IGF-1, making them targeted fat-mobilization tools rather than full hormonal modifiers. This layer increases the rate of fat release, especially when paired with fasted cardio or Zone 2 work. 5️⃣ Structural Fat Reduction (Advanced) Adipotide is reserved for aggressive protocols. It targets adipose vasculature and signals structural fat-mass reduction. This is cycle-based and monitored carefully, used when cosmetic or visceral fat is stubborn. 6️⃣ Muscle Preservation & Anabolic Signaling IGF-1 LR3 is layered during caloric deficit to protect lean tissue. When calories drop and fat loss accelerates, muscle loss risk increases. IGF-1 LR3 provides anabolic signaling to preserve training output and structural mass. 7️⃣ Behavioral Compliance Layer MT2 acts as secondary appetite suppression and behavioral support. It is not foundational but improves adherence during aggressive phases. System Logic This stack works because it addresses every bottleneck: Appetite & insulin control Mitochondrial inefficiency GH rhythm decline Fat mobilization rate Muscle preservation Compliance under deficit Each layer solves a specific constraint. When deployed sequentially rather than simultaneously, the system creates compound leverage. Strategic Outcome When structured correctly, this architecture: Reduces visceral and subcutaneous fat Preserves or improves lean mass Enhances recovery and sleep Increases metabolic flexibility Maintains endocrine integrity It is aggressive but organized. Not chaotic, not redundant, not stimulant-driven. The result is controlled, measurable recomposition — not just weight loss.
Includes
Compliance & Disclaimer
This product is intended for laboratory research purposes only. Not for human consumption. All products are sold with the understanding that the purchaser will comply with all applicable local, state, and federal laws regarding the purchase and use of research chemicals. Certificate of Analysis available upon request.
Related Products

Retatrutide
Triple agonist (GLP-1/GIP/Glucagon) for aggressive fat loss

Fragment 176-191
HGH fat-burning fragment

IGF-1 LR3
Long-acting IGF-1 for growth and hyperplasia

Tesamorelin / Ipamorelin
Premium GH blend for visceral fat loss

Tesamorelin
GHRH analog for visceral fat reduction